Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Laekna takes aim at Truqap as China accepts afuresertib NDA

12 August 2026 · By · Wire by Fusion42

Published

12 August 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

China

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 13 August 2026 · Fusion42 review

Laekna's afuresertib, a pan-AKT inhibitor, has entered regulatory review in China for HR+/HER2- breast cancer, competing against AstraZeneca's approved AKT inhibitor Truqap. The NDA is supported by positive Phase III data and, if approved, afuresertib would be the first domestic AKT inhibitor on the Chinese market.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Chinese biotech founders in oncology have a new benchmark as domestic drug approval processes advance for complex cancer treatments. You can now position your compounds for faster local market entry against multinational incumbents with strong Phase III data.

◆ Coverage

1 source · 12 Aug 2026

◆ Related on Wire

◆ Topics

Biotechchina-regulatorybreast-canceroncology-drugsakt-inhibitorclinical-trial